Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CAP 1002

Drug Profile

CAP 1002

Alternative Names: Allogeneic adult stem cell therapy for myocardial infarction - Capricor; Allogeneic cardiosphere-derived cells - Capricor; Allogeneic CDCs - Capricor; Allogenic derived cells - Capricor; CAP-1002

Latest Information Update: 29 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Capricor
  • Developer Capricor; Capricor Therapeutics; Medical University of South Carolina
  • Class Exosome therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity No
  • Available For Licensing Yes - Duchenne muscular dystrophy

Highest Development Phases

  • Phase III Duchenne muscular dystrophy
  • Phase II COVID 2019 infections
  • Phase I/II Cardiomyopathies
  • Discontinued Heart failure; Myocardial infarction

Most Recent Events

  • 14 Nov 2023 Capricor plans a meeting with the US FDA in the scheduled for late March of 2024.
  • 10 Oct 2023 Updated efficacy data from the phase II HOPE-2-OLE trial in Duchenne Muscular Dystrophy released by Capricor Therapeutics
  • 29 Sep 2023 Capricor Therapeutics plans a follow-up Type B meeting with the US FDA to discuss proposed path towards submission of a potential BLA of CAP 1002 and further discuss its ongoing HOPE-3 clinical trial for Duchenne muscular dystrophy, in early 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top